MARKET

BMY

BMY

Bristol-Myers
NYSE

Real-time Quotes | Nasdaq Last Sale

61.78
-0.40
-0.64%
After Hours: 61.75 -0.03 -0.05% 17:53 12/03 EST
OPEN
62.00
PREV CLOSE
62.18
HIGH
62.29
LOW
61.58
VOLUME
10.94M
TURNOVER
--
52 WEEK HIGH
68.34
52 WEEK LOW
45.76
MARKET CAP
139.61B
P/E (TTM)
-542.4056
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Celgene CVR jumps 121% on hopes for FDA nod on liso-cel by month-end
The contingent value right ((CVR)) issued to Celgene shareholders as part of its $74B merger with Bristol Myers Squibb ([[BMY]] -0.5%) is up 121% today although still down ~13% year to date. Volume is
Seekingalpha · 4h ago
Bristol Myers Deal-Linked Derivative Surges on Inspection Hopes
(Bloomberg) -- The deal sweetener Bristol Myers Squibb Co. offered as a part of its Celgene Corp. purchase spiked as traders positioned ahead of a key year-end deadline and shared optimism related to a needed regulatory inspection.The $9 all-or-nothing payment jumped as much as 55% to the highest level in about three weeks as investors weighed whether U.S. regulators could inspect a facility key to the derivative’s payout in time for a year-end deadline.While traders await word from the company on the state of the inspection, they shared commentary from another drug manufacturer at an Evercore ISI event Wednesday that said a site inspection had just been completed. Fans of the so-called contingent value right, or CVR, viewed the update as a positive sign that the Food and Drug Administration is still inspecting facilities amid the pandemic.The derivative, which has been volatile since plummeting a month ago, depends on FDA approval of the company’s cancer drug lisocabtagene maraleucel by the end of the year as well as approval of a second drug, idecabtagene vicleucel in multiple myeloma, by March 31.Investors have been doing their best to read the tea leaves for what would prove to be a very profitable trade if Bristol Myers can clear the two remaining hurdles. The derivative spiked last week as traders circulated a tweet from FDA Commissioner Stephen Hahn, which signaled the agency is ramping up inspections of drug manufacturing sites.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 6h ago
New Advances in Treating Difficult Blood Cancers From Johnson & Johnson and Others
This coming weekend, doctors who treat blood disorders will convene virtually to discuss new treatments that are extending the lives of patients.
Barrons.com · 2d ago
Worldwide Multiple Myeloma Drugs Industry to 2025 - Players Include Amgen, Bristol-Myers Squibb & Daiichi Sankyo
The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
GlobeNewswire · 2d ago
CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector
New York, New York--(Newsfile Corp. - December 1, 2020) - Portage Biotech (OTC Pink: PTGEF) (CSE: PBT.U) is an emerging biotechnology company developing an immunotherapy focused pipeline to treat a broad range of cancers. Unlike most biotechs though, Portage focuses on combining its own technology with already proven immune-boosting PD1 agents.
Newsfile Corp · 2d ago
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 5d ago
Best Dividend Stocks for December 2020
Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.
Investopedia · 6d ago
Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer
Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Zacks · 11/25 18:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMY stock price target is 74.29 with a high estimate of 88.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 2.76K
Institutional Holdings: 1.74B
% Owned: 76.94%
Shares Outstanding: 2.26B
TypeInstitutionsShares
Increased
851
47.64M
New
218
29.99M
Decreased
893
94.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.36%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Judge
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President/Director of Investor Relations
John Elicker
Executive Vice President
Nadim Ahmed
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Kathryn Metcalfe
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Vice President/Director of Investor Relations/IR Contact Officer
Tim Power
Lead Director/Independent Director
Vicki Sato
Lead Director/Independent Director
vicki Sato
Independent Director
Peter Arduini
Independent Director
Robert Bertolini
Independent Director
Michael Bonney
Independent Director
Matthew Emmens
Independent Director
Julia Haller
Independent Director
Dinesh Paliwal
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Theodore Samuels
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/10/2020
Dividend USD 0.45
10/01/2020
06/11/2020
Dividend USD 0.45
07/02/2020
03/02/2020
Dividend USD 0.45
04/02/2020
12/05/2019
Dividend USD 0.45
01/02/2020
09/11/2019
Dividend USD 0.41
10/03/2019
06/13/2019
Dividend USD 0.41
07/03/2019
03/07/2019
Dividend USD 0.41
04/04/2019
12/06/2018
Dividend USD 0.41
01/03/2019
09/12/2018
Dividend USD 0.4
10/04/2018
06/14/2018
Dividend USD 0.4
07/05/2018
03/01/2018
Dividend USD 0.4
04/05/2018
12/07/2017
Dividend USD 0.4
01/04/2018
09/13/2017
Dividend USD 0.39
10/05/2017
06/14/2017
Dividend USD 0.39
07/05/2017
03/03/2017
Dividend USD 0.39
04/05/2017
12/09/2016
Dividend USD 0.39
01/04/2017
08/04/2016
Dividend USD 0.38
10/05/2016
06/13/2016
Dividend USD 0.38
06/29/2016
03/04/2016
Dividend USD 0.38
03/30/2016
12/10/2015
Dividend USD 0.38
12/30/2015
09/18/2015
Dividend USD 0.37
09/30/2015
06/19/2015
Dividend USD 0.37
07/01/2015
03/05/2015
Dividend USD 0.37
04/01/2015
12/10/2014
Dividend USD 0.37
12/30/2014
09/17/2014
Dividend USD 0.36
10/01/2014
06/18/2014
Dividend USD 0.36
07/01/2014
03/04/2014
Dividend USD 0.36
04/02/2014
12/19/2013
Dividend USD 0.36
12/31/2013
09/18/2013
Dividend USD 0.35
10/02/2013
06/20/2013
Dividend USD 0.35
07/02/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BMY
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.